Idera Pharmaceuticals: Climbs on entering research partnership with AbbVie

Aceragen

04/09/2019 13:09

** Shares of drug developer  IDRA.O  up 8.7% at $2.50
premarket after co announces an immuno-oncology clinical
research collaboration with AbbVie Inc  ABBV.N 
    ** The companies will study the combinations of ABBV's
ABBV-368 with IDRA's lead product candidate tilsotolimod in
treating patients with recurrent or metastatic head and neck
squamous cell carcinoma  urn:newsml:reuters.com:*:nGNX1KQdlQ
    ** Under deal terms, AbbVie will be responsible for
conducting the study and Idera for providing clinical trial
supply of tilsotolimod 
    ** Stock down 17% this year

 (Reporting by Medha Singh in Bengaluru)
 ((medha.singh@thomsonreuters.com))